| Style | Citing Format | 
|---|---|
| MLA | Shahsavari K, et al.. "Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials." BMC Complementary Medicine and Therapies, vol. 24, no. 1, 2024, pp. -. | 
| APA | Shahsavari K, Shams Ardekani MR, Khanavi M, Jamialahmadi T, Iranshahi M, Hasanpour M (2024). Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials. BMC Complementary Medicine and Therapies, 24(1), -. | 
| Chicago | Shahsavari K, Shams Ardekani MR, Khanavi M, Jamialahmadi T, Iranshahi M, Hasanpour M. "Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials." BMC Complementary Medicine and Therapies 24, no. 1 (2024): -. | 
| Harvard | Shahsavari K et al. (2024) 'Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials', BMC Complementary Medicine and Therapies, 24(1), pp. -. | 
| Vancouver | Shahsavari K, Shams Ardekani MR, Khanavi M, Jamialahmadi T, Iranshahi M, Hasanpour M. Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials. BMC Complementary Medicine and Therapies. 2024;24(1):-. | 
| BibTex | @article{ author = {Shahsavari K and Shams Ardekani MR and Khanavi M and Jamialahmadi T and Iranshahi M and Hasanpour M}, title = {Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials}, journal = {BMC Complementary Medicine and Therapies}, volume = {24}, number = {1}, pages = {-}, year = {2024} } | 
| RIS | TY  - JOUR AU - Shahsavari K AU - Shams Ardekani MR AU - Khanavi M AU - Jamialahmadi T AU - Iranshahi M AU - Hasanpour M TI - Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials JO - BMC Complementary Medicine and Therapies VL - 24 IS - 1 SP - EP - PY - 2024 ER - |